(EW) Edwards Lifesciences - Ratings and Ratios
Valves, Heart, Transcatheter, Replacement
EW EPS (Earnings per Share)
EW Revenue
Description: EW Edwards Lifesciences
Edwards Lifesciences Corporation is a leading global provider of innovative cardiovascular solutions, offering a range of products and technologies to treat advanced cardiovascular diseases. The companys transcatheter heart valve replacement products, including the Edwards SAPIEN family of valves, have revolutionized the treatment of aortic heart valves, while its transcatheter heart valve repair and replacement products, such as PASCAL PRECISION and Cardioband, address mitral and tricuspid valve diseases. Additionally, Edwards Lifesciences offers surgical structural heart solutions, including the INSPIRIS and MITRIS RESILIA valves, which feature advanced technologies like RESILIA tissue and VFit.
With a strong presence in the US, Europe, Japan, and internationally, Edwards Lifesciences distributes its products through a combination of direct sales forces and independent distributors. The companys commitment to innovation and quality has enabled it to establish a leadership position in the cardiovascular market. As a result, Edwards Lifesciences has built a reputation for delivering high-quality products that improve patient outcomes and drive growth.
Analyzing the
Based on the
Additional Sources for EW Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
EW Stock Overview
Market Cap in USD | 45,045m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2000-03-27 |
EW Stock Ratings
Growth Rating | -1.78 |
Fundamental | 43.1 |
Dividend Rating | 0.0 |
Rel. Strength | -12.6 |
Analysts | 3.69 of 5 |
Fair Price Momentum | 71.57 USD |
Fair Price DCF | 20.90 USD |
EW Dividends
Currently no dividends paidEW Growth Ratios
Growth Correlation 3m | 61.8% |
Growth Correlation 12m | 52.3% |
Growth Correlation 5y | -53.4% |
CAGR 5y | 2.41% |
CAGR/Max DD 5y | 0.04 |
Sharpe Ratio 12m | -0.53 |
Alpha | -25.48 |
Beta | 0.500 |
Volatility | 28.34% |
Current Volume | 2412k |
Average Volume 20d | 3090.8k |
Stop Loss | 73.7 (-3.5%) |
As of July 09, 2025, the stock is trading at USD 76.39 with a total of 2,411,983 shares traded.
Over the past week, the price has changed by -1.02%, over one month by +0.04%, over three months by +13.90% and over the past year by -16.82%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Edwards Lifesciences (NYSE:EW) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 43.11 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EW is around 71.57 USD . This means that EW is currently overvalued and has a potential downside of -6.31%.
Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefor, it is recommend to hold EW.
- Strong Buy: 10
- Buy: 4
- Hold: 17
- Sell: 0
- Strong Sell: 1
According to our own proprietary Forecast Model, EW Edwards Lifesciences will be worth about 80.3 in July 2026. The stock is currently trading at 76.39. This means that the stock has a potential upside of +5.13%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 81 | 6% |
Analysts Target Price | 80.9 | 5.9% |
ValueRay Target Price | 80.3 | 5.1% |